Delivery Order SPE2DB22D2206-SPE2DB25FEZ87

Award Date 1/7/25
Potential Completion Date 1/8/25
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,935.80 firm fixed-price delivery order is for the supply of Olopatadine HCl 0.1% eye drops in 5ml bottles. The contract has an ultimate completion date of September 15, 2022 and was awarded on September 14, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of OLOPATADINE HCL 0.1% eye drops in 5ML bottles. The $1,115.33 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. The contract has an ultimate completion date of November 18, 2024 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the supply of Olopatadine Hydrochloride 0.1% eye drops. The $1,297.14 delivery order is a firm-fixed price contract with an ultimate completion date of April 24, 2024. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 with the DLA Troop Support Medical, which serves as the primary...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the provision of Olopatadine HCL 0.1% eye drops, 5ml, with a completion date of January 30, 2024 and a potential value of $1,026.12. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Olopatadine HCL 0.1% eye drops in 5 mL containers. The fixed-price, firm-fixed delivery order contract has an ultimate completion date of March 2, 2023 and a ceiling value of $2,777.51. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of OLOPATADINE HCL 0.1% EYE DROPS 5ML. The firm fixed-price delivery order has a ceiling value of $3,173.87 and a completion date of September 11, 2024. This contract is not set aside for any special designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of Olopatadine HCL 0.1% eye drops (5 ml) to the Defense Logistics Agency (DLA). The contract is a $6,433.70 Firm Fixed Price Delivery Order with a period of performance through July 11, 2024. Amerisourcebergen holds a larger, single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999.00 through December 31, 2025. This IDC serves as the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olopatadine Hydrochloride 0.1% Eye Drops. The $3,218.10 fixed-price delivery order contract has a completion date of September 20, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with DLA Troop Support Medical and the Department of Justice Federal Bureau of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,129.24 Firm Fixed Price Delivery Order is for the supply of 4566734959 - Olopatadine HCl 0.1% Eye Drops, 5ML. The contract has a completion date of December 17, 2024 and was awarded on December 16, 2024. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The $2,090.15 award is for the provision of 4,564,247,570 units of Olopatadine HCL 0.1% eye drops in 5ml containers. No set-aside designation was used. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FEZ87
    Delivery Order

This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OLOPATADINE HCL 0.1% EYE DROPS 5ML. The contract has a ceiling value of $2,887.30 and a completion date of January 8, 2025. It is a Firm Fixed Price contract with no set-aside designation, indicating open competition.

AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 4/8/25, 9:44 AM